We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Anthony
Schapira
a.schapira@ucl.ac.uk
Georgie
Pittwood
rapsodi@ucl.ac.uk
Milly
Anderson
rapsodi@ucl.ac.uk
Study
Team
rapsodi@ucl.ac.uk
Nadine
Loefflad
rapsodi@ucl.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Extrapyramidal and movement disordersMetabolic disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
This project aims to remotely detect the early signs and symptoms of Parkinson's disease (PD) in a group of patients who carry a gene (glucocerebrosidase-GBA) which causes a genetic predisposition to it. We aim to detect these signs and symptoms prior to the clinically diagnostic onset of the movement related (motor) symptoms of the disease. We will assess for signs and symptoms including anxiety, depression, bradykinesia (slowness of movement), cognitive decline, reduced sense of smell, abnormal sleep behaviours, constipation and erectile dysfunction associated with the very early stages of PD. Participants will be required to undertake a questionnaire and a number of interactive assessments, which are designed to identify risk factors and early clinical signs of Parkinson's. Participants will be genotyped in order to establish genetic factors which determine those who do and do not develop PD. The answers to this questionnaire/assessments/genotyping will be stored in a secure internet database and will generate a risk score. Blood, urine and cerebrospinal fluid will be analysed to look for biological markers that predict the onset of PD. Under most circumstances the study will be undertaken entirely at the participant's home, either through an internet portal or with the use of postal assessments. We intend that this study will enable us to understand and describe the early stages of PD in this patient group and provide insights into the genetic risk factors that contribute to it.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
1. GBA negative (i.e control) individuals with a diagnosis of Parkinson's disease 2.Other forms of Parkinsonism (progressive supranuclear palsy, multiple system atrophy, traumatic, manganese toxicity, postencephalitic, vascular PD; drug induced PD; corticobasal degeneration). 3.Individuals with another neurological disorder including: dementia, movement disorders, stroke, motor neurone disease. 4.Individuals on drugs known to be associated with parkinsonism, including neuroleptic agents (Amisulpride, Chlorpromazine Hydrocloride, Flupenthixol, Fluphenazine Hydrochloride, Haloperidol, Methotrimeprazine, Levomepromazine, Olanzapine, Oxypertine, Pericyazine, Perphenazine, Pimozide, Pipotiazine, Prochlorperazine, Promazine Hydrochloride, Reserpine, Risperidone, Sulpiride, Thioridazine, Trifluoperazine, Zuclopenthixol acetate, Zotepine), plus Bupropion, Lithium, Methyldopa, Metoclopramide and Sodium Valproate)
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Anthony
Schapira
a.schapira@ucl.ac.uk
Nadine
Loefflad
rapsodi@ucl.ac.uk
Study
Team
rapsodi@ucl.ac.uk
Georgie
Pittwood
rapsodi@ucl.ac.uk
Milly
Anderson
rapsodi@ucl.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by University College London and funded by Medical Research Council (MRC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 19739
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
